Peter D. Senter

Seattle Genetics (United States)
United States

D-Index & Metrics D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines.

Discipline name Citations Publications World Ranking National Ranking

Biology and Biochemistry D-index 76 Citations 26,334 231 World Ranking 3102 National Ranking 1605

Overview

What are the main themes of his work throughout his whole career to date

His study ties his expertise on Bone marrow together with the subject of Immunology. Peter D. Senter regularly links together related areas like Immunology in his Bone marrow studies. In his study, he carries out multidisciplinary Antibody and Complement-dependent cytotoxicity research. Peter D. Senter connects Complement-dependent cytotoxicity with Complement system in his study. Peter D. Senter conducts interdisciplinary study in the fields of Complement system and Antibody-dependent cell-mediated cytotoxicity through his works. His Antibody-dependent cell-mediated cytotoxicity study frequently draws connections between adjacent fields such as Cytotoxicity. Many of his studies involve connections with topics such as Biochemistry and Cytotoxicity. His Biochemistry study frequently draws connections to adjacent fields such as Ribosome. Peter D. Senter integrates Ribosome and Gene in his research.

Peter D. Senter most often published in these fields:

Immunology (100.00%)
Antibody (100.00%)
Biochemistry (100.00%)

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Development of potent monoclonal antibody auristatin conjugates for cancer therapy.

Svetlana O Doronina;Brian E Toki;Michael Y Torgov;Brian A Mendelsohn.
Nature Biotechnology (2003)

1646 Citations

Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug Conjugate

Kevin J. Hamblett;Peter D. Senter;Dana F. Chace;Michael M. C. Sun.
Clinical Cancer Research (2004)

1335 Citations

Arming antibodies: prospects and challenges for immunoconjugates

Anna M Wu;Peter D Senter.
Nature Biotechnology (2005)

1300 Citations

cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity.

Joseph A Francisco;Charles G Cerveny;Damon L Meyer;Bruce J Mixan.
Blood (2003)

1143 Citations

Monomethylvaline compounds capable of conjugation to ligands

Allen J Ebens;Brian E Toki;Mark X Sliwkowski;Paul Polakis.
(2004)

1100 Citations

Antibody–drug conjugates: targeted drug delivery for cancer

Stephen C Alley;Nicole M Okeley;Peter D Senter.
Current Opinion in Chemical Biology (2010)

817 Citations

Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells

Peter D. Senter;Mark G. Saulnier;Joseph P. Brown;David E. Kerr.
(1988)

747 Citations

The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma

Peter D Senter;Eric L Sievers.
Nature Biotechnology (2012)

737 Citations

Antibody-Drug Conjugates in Cancer Therapy

Eric L Sievers;Peter D Senter.
Annual Review of Medicine (2013)

736 Citations

Enhanced Activity of Monomethylauristatin F through Monoclonal Antibody Delivery: Effects of Linker Technology on Efficacy and Toxicity

Svetlana O. Doronina;Brian A. Mendelsohn;Tim D. Bovee;Charles G. Cerveny.
Bioconjugate Chemistry (2006)

670 Citations

If you think any of the details on this page are incorrect, let us know.

Frequent Co-Authors

External Links

Personal Website for Peter D. Senter